Good Steward Wealth Advisors LLC Makes New $269,000 Investment in Kenvue Inc. (NYSE:KVUE)

Good Steward Wealth Advisors LLC acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the 1st quarter, Holdings Channel.com reports. The institutional investor acquired 11,220 shares of the company’s stock, valued at approximately $269,000.

Several other institutional investors also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its position in shares of Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock worth $5,249,665,000 after buying an additional 8,211,748 shares during the period. Vanguard Group Inc. increased its stake in Kenvue by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock worth $4,665,908,000 after acquiring an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Geode Capital Management LLC raised its holdings in shares of Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock worth $980,989,000 after purchasing an additional 1,391,854 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock valued at $912,059,000 after purchasing an additional 16,269,721 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE stock opened at $21.35 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. The company’s fifty day moving average price is $23.01 and its two-hundred day moving average price is $22.45. The firm has a market capitalization of $40.95 billion, a P/E ratio of 38.81, a P/E/G ratio of 3.32 and a beta of 0.98. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The company’s revenue for the quarter was down 3.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.28 earnings per share. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date was Wednesday, May 14th. Kenvue’s payout ratio is 149.09%.

Analyst Upgrades and Downgrades

KVUE has been the subject of a number of research analyst reports. Evercore ISI initiated coverage on shares of Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 target price for the company. Barclays raised their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday, May 12th. Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Citigroup reissued a “neutral” rating on shares of Kenvue in a research report on Friday, June 13th. Finally, Redburn Atlantic started coverage on Kenvue in a research report on Thursday, April 10th. They issued a “neutral” rating and a $23.50 target price for the company. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.